Atara Biotherapeutics Announces Collaborator Presentation of Positive Phase 1 Clinical Results for a Mesothelin-Targeted CAR T Immunotherapy in Patients with Advanced Mesothelioma - Nasdaq
Atara Biotherapeutics Announces Collaborator Presentation of Positive Phase 1 Clinical Results for a Mesothelin-Targeted CAR T Immunotherapy in Patients with Advanced Mesothelioma Nasdaq
Memorial Sloan Kettering Cancer Center collaborators presented results that a regionally delivered mesothelin-targeted, autologous CAR T was.
Comments
Post a Comment